Hikma Launches Azacitidine
On September 10, Hikma Pharmaceuticals PLC (Hikma), at London announced Azacitidine for Injection, 100 mg, the generic version of Vidaza, in the United States it…
Medications
FDA Approval For RET Cancer Drug Gavreto
Recently FDA Okayed Gavreto (pralsetinib) for the treatment of adults with metastatic RET fusion-positive non-small cell lung cancer. Gavreto approved under the FDA’s accelerated approval…
No Link Between Antihypertensive and Cancer Risk
According to the press release from ESC (European Society of Cardiology), there is no evidence that blood pressure lowering drugs (antihypertensive as an example) increase…
Dapagliflozin Reduces Risk of Kidney Failure
Recently was confirmed, that treatment with dapagliflozin (Farxiga; AstraZeneca) reduced the risk of kidney failure and cardiovascular (CV) or renal death in patients with chronic…
ESC: Vascepa Reduces Patients’ Arterial Plaque
According to the information from the European Society of Cardiology’s (ESC) virtual annual meeting, which was at August 29 Vascepa cut patients’ coronary plaque by…
FDA Balks At Bayshore Recall
After the information from FDA about Bayshore Pharmaceuticals, LLC recall. It was a voluntary nationwide Bayshore recall of metformin hydrochloride extended-release tablets. The FDA begins…
Bayshore Pharmaceuticals Metformin Recall
At August 19 Bayshore Pharmaceuticals, LLC announced recalling one (1) lot of Metformin Hydrochloride Extended-Release Tablets USP, 500 mg, 1000 count bottles and one (1)…
Multiple Sclerosis Treatment From Mylan
The FDA Okayed first in The US oral solid solutions from Mylan for MS treatment. MS (Multiple Sclerosis) is The disease mainly occurs at a…
FDA Approves Satralizumab-mwge
17 August media got the information about the FDA approvement for Enspryng (Genentech) Satralizumab-mwge for the treatment of neuromyelitis optica spectrum disorder (MNOSD) in adults…
NACDS: Drug Discount Cards Rates Should Be Fixed
NACDS: “For consumers on tight budgets who rely on third-party drug discount cards to pay for their medications, the potential loss of access to these…